Freeline_Logo_Red_RGB.jpg
Freeline Announces September 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 oct. 2022 16h01 HE | Freeline Therapeutics Holdings plc
LONDON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on September 30, 2022, the Company granted five newly hired employees non-statutory...
Freeline_Logo_Red_RGB.jpg
Freeline Initiates Dosing of Second Cohort in MARVEL-1 Trial of FLT190 Gene Therapy Candidate for People with Fabry Disease
04 oct. 2022 07h00 HE | Freeline Therapeutics Holdings plc
LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the first patient has been dosed in the second dose cohort of the Phase 1/2 MARVEL-1...
Freeline_Logo_Red_RGB.jpg
Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress
10 juil. 2022 03h00 HE | Freeline Therapeutics
FLT180a generated protective FIX levels with no bleeding or need for FIX replacement The treatment was well tolerated with a good safety profile LONDON, July 10, 2022 (GLOBE NEWSWIRE) -- Freeline...
Freeline_Logo_Red_RGB.jpg
Freeline Announces June 2022 Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 juil. 2022 16h01 HE | Freeline Therapeutics
LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on June 30, 2022, the Company granted a newly hired employee non-statutory options to...
Freeline_Logo_Red_RGB.jpg
Freeline Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
03 juin 2022 16h01 HE | Freeline Therapeutics
LONDON, June 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today disclosed the receipt of a notice (the “Notice”) on May 31, 2022 from...
Freeline_Logo_Red_RGB.jpg
Freeline Reports First Quarter 2022 Financial Results and Business Highlights
10 mai 2022 16h01 HE | Freeline Therapeutics
Phase 1/2 clinical programs in Hemophilia B, Gaucher disease and Fabry disease on track to deliver 2022 milestones Recent appointment of new Chief Financial Officer further strengthens leadership...
Freeline_Logo_Red_RGB.jpg
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 mai 2022 16h01 HE | Freeline Therapeutics
LONDON, May 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that on April 29, 2022, the Company granted five newly hired...
Freeline_Logo_Red_RGB.jpg
Freeline To Present at the 25th Annual Meeting of the American Society of Gene and Cell Therapy
02 mai 2022 17h10 HE | Freeline Therapeutics
LONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced the upcoming presentation of five posters at the 25th Annual...
Freeline_Logo_Red_RGB.jpg
Freeline Appoints Paul Schneider as Chief Financial Officer
19 avr. 2022 08h01 HE | Freeline Therapeutics
LONDON, April 19, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that Paul M. Schneider has been appointed Chief Financial...
Freeline_Logo_Red_RGB.jpg
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 mars 2022 16h01 HE | Freeline Therapeutics
LONDON, March 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that on February 28, 2022, the Company granted three newly...